Last reviewed · How we verify
GenSci004
GenSci004 is a recombinant human growth hormone analog designed to promote growth and metabolic effects.
GenSci004 is a recombinant human growth hormone analog designed to promote growth and metabolic effects. Used for Growth hormone deficiency, Growth disorders in children.
At a glance
| Generic name | GenSci004 |
|---|---|
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Drug class | Growth hormone analog |
| Target | Growth hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
GenSci004 acts as a growth hormone receptor agonist, binding to and activating growth hormone receptors to stimulate growth, protein synthesis, and metabolic processes. The drug is developed as a therapeutic option for growth hormone deficiency and related growth disorders.
Approved indications
- Growth hormone deficiency
- Growth disorders in children
Common side effects
- Injection site reactions
- Headache
- Joint pain
- Carpal tunnel syndrome
Key clinical trials
- A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency (PHASE3)
- A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |